Details of the Drug

General Information of Drug (ID: DMWSA0V)

Drug Name

Patisiran

Synonyms

Patisiran [INN]; Patisiran [USAN:INN]; UNII-50FKX8CB2Y; 50FKX8CB2Y; ALN-18328

Indication

Disease Entry	ICD 11	Status	REF
Amyloidosis	5D00	Approved	[1]
Hereditary amyloidosis	5D00.2	Approved	[2]
Amyloid cardiomyopathy	5D00.20	Phase 3	[3]
Transthyretin familial amyloid cardiomyopathy	5D00.20	Phase 3	[4]

Affected Organisms

Humans and other mammals

ATC Code

N07XX12: Patisiran

N07XX: Other nervous system drugs

N07X: OTHER NERVOUS SYSTEM DRUGS

N07: OTHER NERVOUS SYSTEM DRUGS

N: NERVOUS SYSTEM

Drug Type

siRNA drug

Sequence

>Subunit 1
GUAACCAAGAGUAUUCCAUTT
>Subunit 2
AUGGAAUACUCUUGGUUACTT

Structure

3D Structure is Not Available

3D MOL is unavailable

2D MOL

ADMET Property

Clearance: The total body clearance of drug is 3.0 +/- 2.5 mL/h/kg []
Elimination: The bulk of the drug is broken down by nucleases, and less than 1% is excreted through the urine []
Half-life: The concentration or amount of drug in body reduced by one-half in 3.2 +/- 1.8 days []
Metabolism: The drug is metabolized via nucleases []
Vd: The volume of distribution (Vd) of drug is 0.26 +/- 0.20 L/kg []

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Transthyretin messenger RNA (TTR mRNA)	TTPOYU7	TTHY_HUMAN	Not Available	[5]

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2018. Application Number: (ANDA) 210922.
2	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	ClinicalTrials.gov (NCT01960348) APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis. U.S. National Institutes of Health.
5	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc.